TN2011000247A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2011000247A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; optionally; 1hor; thioxo; pyrazolo
Prior art date: 2008-12-06

Application number

TN2011000247A

Other languages

English (en)

Inventor

Lawrence P Wennogle

Peng Li

Zhao Jun

Zeng Hailin

Original Assignee

Intra Cellular Therapies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-06

Filing date

2011-05-17

Publication date

2012-12-17

2011-05-17 Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc

2012-12-17 Publication of TN2011000247A1 publication Critical patent/TN2011000247A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Addiction (AREA)

TN2011000247A 2008-12-06 2011-05-17 Organic compounds TN2011000247A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12044108P	2008-12-06	2008-12-06
PCT/US2009/006442 WO2010065151A1 (fr)	2008-12-06	2009-12-07	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2011000247A1 true TN2011000247A1 (en)	2012-12-17

Family

ID=42233535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000247A TN2011000247A1 (en)	2008-12-06	2011-05-17	Organic compounds

Country Status (23)

Country	Link
US (3)	US8633180B2 (fr)
EP (1)	EP2358723B1 (fr)
JP (2)	JP5989993B2 (fr)
KR (1)	KR20110096032A (fr)
CN (1)	CN102232077A (fr)
AU (1)	AU2009322903A1 (fr)
BR (1)	BRPI0922808A2 (fr)
CA (1)	CA2740394A1 (fr)
CO (1)	CO6400146A2 (fr)
CR (1)	CR20110313A (fr)
DO (1)	DOP2011000175A (fr)
EA (1)	EA201170771A1 (fr)
EC (1)	ECSP11011182A (fr)
ES (1)	ES2544976T3 (fr)
GE (1)	GEP20146030B (fr)
IL (1)	IL213313A0 (fr)
MA (1)	MA32942B1 (fr)
MX (1)	MX2011005937A (fr)
PE (1)	PE20120209A1 (fr)
SG (1)	SG171776A1 (fr)
TN (1)	TN2011000247A1 (fr)
WO (1)	WO2010065151A1 (fr)
ZA (1)	ZA201103632B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1888534B1 (fr)	2005-06-06	2017-07-26	Intra-Cellular Therapies, Inc.	Composés organiques
CA2651519A1 (fr)	2006-06-06	2007-12-13	Intra-Cellular Therapies, Inc.	Composes organiques
EP2081431B1 (fr) *	2006-11-13	2013-01-16	Intra-Cellular Therapies, Inc.	Composés organiques
JP5837278B2 (ja)	2006-12-05	2015-12-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
JP5701608B2 (ja) *	2007-12-06	2015-04-15	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
WO2009075784A1 (fr)	2007-12-06	2009-06-18	Intra-Cellular Therapies, Inc.	Composés organiques
GEP20146046B (en)	2008-12-06	2014-02-25	Intracellular Therapies Inc	Organic compounds
US8536159B2 (en)	2008-12-06	2013-09-17	Intra-Cellular Therapies, Inc.	Organic compounds
PE20110834A1 (es)	2008-12-06	2011-12-14	Intra Cellular Therapies Inc	DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
AU2009322900A1 (en) *	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
JP2012518685A (ja) *	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (fr)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Composés organiques
US8858911B2 (en)	2009-10-08	2014-10-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2590657A4 (fr)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Composés organiques
EP2575817A4 (fr)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Composés organiques
US10561656B2 (en)	2011-06-10	2020-02-18	Intra-Cellular Therapies, Inc.	Organic compounds
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
EP2956141A4 (fr)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	Nouvelles utilisations
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
ES2871327T3 (es)	2013-03-15	2021-10-28	Intra Cellular Therapies Inc	Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP
MX2015017972A (es)	2013-06-21	2016-10-28	Intra Cellular Therapies Inc	Cristales de base libre.
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
ES2732442T3 (es) *	2014-06-20	2019-11-22	Intra Cellular Therapies Inc	Compuestos orgánicos
CA2951284A1 (fr)	2014-07-29	2016-02-04	Therapeuticsmd, Inc.	Creme transdermique
EP3177627B1 (fr) *	2014-08-07	2019-07-24	Intra-Cellular Therapies, Inc.	Derives de imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one avec activite inhibitrice de la pde1
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
EP3725789B1 (fr)	2014-09-17	2022-03-09	Intra-Cellular Therapies, Inc.	Dérivés de 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one en tant qu'inhibiteurs de phosphodiestérase 1 (pde1) pour le traitement de maladies, troubles ou blessures du sytème nerveux central (snc)
KR102557603B1 (ko)	2014-12-06	2023-07-19	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
JP6608933B2 (ja)	2014-12-06	2019-11-20	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
KR102483124B1 (ko) *	2016-03-25	2022-12-29	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2017173044A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
CA3020153A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Composition pharmaceutique d'hormone steroide
WO2018049417A1 (fr)	2016-09-12	2018-03-15	Intra-Cellular Therapies, Inc.	Nouvelles utilisations
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
EP4520399A3 (fr)	2018-05-25	2025-03-26	Intra-Cellular Therapies, Inc.	Composés organiques
WO2020146384A1 (fr)	2019-01-07	2020-07-16	Intra-Cellular Therapies, Inc.	Composés organiques
US11628171B2 (en)	2019-03-13	2023-04-18	Children's Medical Center Corporation	Method for treating brain or nerve injury
EP3953358A4 (fr)	2019-04-12	2023-01-04	Intra-Cellular Therapies, Inc.	Composés organiques
JP7612672B2 (ja) *	2019-09-03	2025-01-14	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規化合物
KR20220054853A (ko) *	2019-09-03	2022-05-03	인트라-셀룰라 써래피스, 인코퍼레이티드.	치료 방법
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
US12435093B2 (en)	2020-05-06	2025-10-07	Intra-Cellular Therapies, Inc.	Free base crystals
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
IL98559A0 (en)	1990-06-21	1992-07-15	Schering Corp	Polycyclic guanine derivatives
US5202328A (en)	1991-03-06	1993-04-13	Merck & Co., Inc.	Substituted fused pyrimidinones
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
IL108754A0 (en)	1993-02-26	1994-06-24	Schering Corp	2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9315017D0 (en)	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en)	1997-10-17	2000-01-11	The Rockfeller University	Method of treating psychosis and/or hyperactivity
GB9722520D0 (en)	1997-10-24	1997-12-24	Pfizer Ltd	Compounds
US6133273A (en)	1998-05-08	2000-10-17	American Home Products Corporation	Pyrazolopyrimidine-2,4-dione sulfonamides
DE19931206A1 (de)	1999-07-07	2001-01-11	Stief Christian	Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
EP1218379A2 (fr)	1999-09-30	2002-07-03	Neurogen Corporation	PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO 1,5-a]-1,3,5-TRIAZINES
AU7547900A (en)	1999-10-11	2001-04-23	Pfizer Inc.	5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL152925A (en)	1999-10-21	2010-04-15	Pfizer	Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
CA2407031A1 (fr)	2000-04-19	2001-10-25	Lilly Icos Llc	Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
EP1372656B1 (fr)	2001-03-16	2005-06-22	Pfizer Limited	Composes pyrazolo[4,3-d]pyrimidinone en tant qu'inhibiteurs de gmpc pde
WO2002088079A2 (fr)	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Inhibiteurs doubles de pde 7 et pde 4
SE0102315D0 (sv)	2001-06-28	2001-06-28	Astrazeneca Ab	Compounds
CA2457944C (fr)	2001-08-28	2009-09-29	Schering Corporation	Inhibiteurs polycycliques de la phosphodiesterase v de la guanine
CA2459161A1 (fr)	2001-08-31	2003-03-13	The Rockefeller University	Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
JP2005509038A (ja)	2001-11-09	2005-04-07	シェーリング　コーポレイション	多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
WO2003072801A2 (fr)	2002-02-21	2003-09-04	The Rockefeller University	Compositions et methodes de regulation de la signalisation dependant du calcium dans le cerveau
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
WO2004087906A1 (fr)	2003-03-31	2004-10-14	Pfizer Products Inc.	Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations
WO2004087211A2 (fr)	2003-04-01	2004-10-14	Applied Research Systems Ars Holding N.V.	Inhibiteurs de phosphodiesterases dans l'infecondite
AP2006003559A0 (en)	2003-09-05	2006-04-30	Neurogen Corp Ventis Pharmaceuticals Inc	Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
EP1888534B1 (fr)	2005-06-06	2017-07-26	Intra-Cellular Therapies, Inc.	Composés organiques
US20080194592A1 (en)	2005-08-23	2008-08-14	Intra-Cellular Therapies, Inc.	Organic Compounds
CA2651519A1 (fr)	2006-06-06	2007-12-13	Intra-Cellular Therapies, Inc.	Composes organiques
US20070286890A1 (en)	2006-06-07	2007-12-13	John Garnett Walt	Eyelash applicator and method
EP2081431B1 (fr)	2006-11-13	2013-01-16	Intra-Cellular Therapies, Inc.	Composés organiques
JP5837278B2 (ja) *	2006-12-05	2015-12-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
JP5701608B2 (ja)	2007-12-06	2015-04-15	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
WO2009075784A1 (fr)	2007-12-06	2009-06-18	Intra-Cellular Therapies, Inc.	Composés organiques
GEP20146046B (en)	2008-12-06	2014-02-25	Intracellular Therapies Inc	Organic compounds
PE20110834A1 (es)	2008-12-06	2011-12-14	Intra Cellular Therapies Inc	DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
US8536159B2 (en)	2008-12-06	2013-09-17	Intra-Cellular Therapies, Inc.	Organic compounds
AU2009322900A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
JP2012518685A (ja)	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (fr)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Composés organiques
US8858911B2 (en)	2009-10-08	2014-10-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
EP2590657A4 (fr)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Composés organiques
EP2575817A4 (fr)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Composés organiques

2009
- 2009-12-07 EP EP20090830746 patent/EP2358723B1/fr active Active
- 2009-12-07 KR KR1020117013125A patent/KR20110096032A/ko not_active Withdrawn
- 2009-12-07 US US13/133,082 patent/US8633180B2/en active Active
- 2009-12-07 EA EA201170771A patent/EA201170771A1/ru unknown
- 2009-12-07 MX MX2011005937A patent/MX2011005937A/es not_active Application Discontinuation
- 2009-12-07 AU AU2009322903A patent/AU2009322903A1/en not_active Abandoned
- 2009-12-07 CA CA2740394A patent/CA2740394A1/fr not_active Abandoned
- 2009-12-07 WO PCT/US2009/006442 patent/WO2010065151A1/fr not_active Ceased
- 2009-12-07 SG SG2011036597A patent/SG171776A1/en unknown
- 2009-12-07 BR BRPI0922808A patent/BRPI0922808A2/pt not_active IP Right Cessation
- 2009-12-07 MA MA33973A patent/MA32942B1/fr unknown
- 2009-12-07 ES ES09830746.5T patent/ES2544976T3/es active Active
- 2009-12-07 GE GEAP200912254A patent/GEP20146030B/en unknown
- 2009-12-07 PE PE2011001172A patent/PE20120209A1/es not_active Application Discontinuation
- 2009-12-07 JP JP2011539521A patent/JP5989993B2/ja not_active Expired - Fee Related
- 2009-12-07 CN CN2009801481881A patent/CN102232077A/zh active Pending
2011
- 2011-05-17 TN TN2011000247A patent/TN2011000247A1/fr unknown
- 2011-05-17 ZA ZA2011/03632A patent/ZA201103632B/en unknown
- 2011-06-02 IL IL213313A patent/IL213313A0/en unknown
- 2011-06-06 CR CR20110313A patent/CR20110313A/es unknown
- 2011-06-06 DO DO2011000175A patent/DOP2011000175A/es unknown
- 2011-06-29 CO CO11081349A patent/CO6400146A2/es not_active Application Discontinuation
- 2011-07-05 EC EC2011011182A patent/ECSP11011182A/es unknown
2013
- 2013-09-06 US US14/019,950 patent/US20140011783A1/en not_active Abandoned
2014
- 2014-06-04 US US14/296,145 patent/US20150080357A1/en not_active Abandoned
2015
- 2015-05-27 JP JP2015107697A patent/JP2016006042A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2012510994A (ja)	2012-05-17
MX2011005937A (es)	2011-12-16
US20120071450A1 (en)	2012-03-22
WO2010065151A1 (fr)	2010-06-10
CA2740394A1 (fr)	2010-06-10
EP2358723A1 (fr)	2011-08-24
KR20110096032A (ko)	2011-08-26
ECSP11011182A (es)	2011-10-31
EP2358723B1 (fr)	2015-05-13
IL213313A0 (en)	2011-07-31
ZA201103632B (en)	2013-05-29
DOP2011000175A (es)	2011-10-31
SG171776A1 (en)	2011-07-28
MA32942B1 (fr)	2012-01-02
PE20120209A1 (es)	2012-03-18
US20140011783A1 (en)	2014-01-09
EA201170771A1 (ru)	2012-01-30
JP5989993B2 (ja)	2016-09-07
JP2016006042A (ja)	2016-01-14
AU2009322903A1 (en)	2010-06-10
US20150080357A1 (en)	2015-03-19
GEP20146030B (en)	2014-02-10
CO6400146A2 (es)	2012-03-15
EP2358723A4 (fr)	2012-10-10
ES2544976T3 (es)	2015-09-07
CN102232077A (zh)	2011-11-02
BRPI0922808A2 (pt)	2018-05-29
US8633180B2 (en)	2014-01-21
CR20110313A (es)	2011-10-28

Publication	Publication Date	Title
TN2011000247A1 (en)	2012-12-17	Organic compounds
PT2240490E (pt)	2013-12-09	Compostos orgânicos
TN2011000245A1 (en)	2012-12-17	Organic compounds
MX2011005933A (es)	2011-12-16	Compuestos organicos.
WO2012007345A3 (fr)	2012-04-12	Imidazo[1,2-a]pyrimidines et -pyridines substitués
TN2011000244A1 (en)	2012-12-17	Organic compounds
TN2011000249A1 (en)	2012-12-17	Organic compounds
GEP20135780B (en)	2013-03-11	Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
IL204693A0 (en)	2010-11-30	Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
EP2608669A4 (fr)	2014-01-22	Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
ZA201004368B (en)	2013-01-30	Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IN2012DN02577A (fr)	2015-08-28
MX352831B (es)	2017-12-11	Cristales de sal.
AU2011288503A8 (en)	2013-01-10	6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
MX2011008452A (es)	2011-12-16	Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
PH12012501749A1 (en)	2015-02-25	Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
WO2010011546A3 (fr)	2010-08-12	Composés acycliques ayant une affinité pour le récepteur 5-ht6
MX2008011576A (es)	2008-09-22	Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
WO2009034547A3 (fr)	2009-06-25	Nouveaux dérivés 4-substitués de la pyrazolo[3,4-d]pyrimidine et de la pyrrolo[2,3-d]pyrimidine et leurs utilisations
MX347948B (es)	2017-05-19	Moduladores de los receptores 5-ht y metodos de uso de los mismos.
SI1869038T1 (sl)	2009-12-31	Substituirane 5,6,7,8-tetrahidro-imidazo(1,2-a)piridin-2-ilaminske spojine in njihova uporaba za pripravo zdravil
WO2007031977A3 (fr)	2007-06-07	Inhibiteurs de la phosphodiesterase
CY1114796T1 (el)	2016-12-14	Οργανικες ενωσεις
WO2012136356A8 (fr)	2013-01-03	Dérivés de la 6,7-dihydro-[1,3,4] thiadiazolo-[3,2-a][1,3] diazépine et compositions pharmaceutiques les contenant en tant qu'agent hypnotique ou anesthésique et procédé pour leur préparation
NZ593340A (en)	2012-12-21	Bicyclic derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics